Literature DB >> 24526568

From sarcopenia to frailty: a road less traveled.

John E Morley1, Stephan von Haehling, Stefan D Anker, Bruno Vellas.   

Abstract

The physical frailty phenotype consists of fatigue, weight loss, and loss of muscle power. Sarcopenia has been shown to be a major cause of frailty. Six societies including SCWD published a consensus suggesting that all persons older than 70 years of age should be screened for frailty when seeing health professionals. Simple screening tests such as the FRAIL (fatigue, resistance, aerobic, illness, and loss of weight) scale can be used. It is felt that frailty can be treated by exercise (resistance and aerobic), high quality protein, vitamin D, and treatment of the common causes of fatigue. It is expected that this approach will decrease disability in older persons.

Entities:  

Year:  2014        PMID: 24526568      PMCID: PMC3953315          DOI: 10.1007/s13539-014-0132-3

Source DB:  PubMed          Journal:  J Cachexia Sarcopenia Muscle        ISSN: 2190-5991            Impact factor:   12.910


Introduction

Health-care professionals are accustomed to seeing frail older persons, but rarely do they recognize the role of sarcopenia in the pathogenesis of frailty. Even more rarely do they institute an aggressive treatment regimen to improve the older person’s quality of life. For this reason, six societies, including the SCWD, published a consensus statement that defined frailty as “a medical syndrome with multiple causes and contributors that is characterized by diminished strength, endurance and reduced physiologic function that increases an individual’s vulnerability for developing increased dependency and/or death” [1]. They further agreed that frailty is a treatable condition. For this reason, they agreed that “all persons older than 70 years and all individuals with significant weight loss (5 %) due to chronic disease, should be screened for frailty.” An objective definition for a physical frailty phenotype was created and validated in 2001 by Fried et al. [2]. Their definition included weight loss, exhaustion, weakness (grip strength), walking speed, and low physical activity. They found that it was present in approximately 7 % of persons in the cardiovascular health study. Based on this schema, a simple five-point questionnaire was developed by the International Association of Nutrition and Aging (Table 1) [3]. Another approach to frailty screening was developed by Rockwood et al. [4]. This consists of adding together all the deficits a person has and then mathematically designating a frailty score. While this is highly predictive of poor outcomes, it is more of a comorbid score than a physical frailty index. It has also been recognized that persons with psychosocial frailty as well as physical frailty tend to have even worse outcomes [5-10].
Table 1

The simple FRAIL scale

Fatigue
Resistance (can you climb a flight of stairs?)
Aerobic (can you walk a block?)
Illness (>5)
Loss of weight (5 % in 6 months)

Three or more positive answers, frail; one or two positive answers, prefrail

The simple FRAIL scale Three or more positive answers, frail; one or two positive answers, prefrail The FRAIL (fatigue, resistance, aerobic, illness, and loss of weight) scale has been validated by six separate studies and appears to perform as well as the other more complex scales [11-16]. Of the five components of the FRAIL scale, both resistance (climb a flight of stairs) and aerobic (walk one block) are clearly components of sarcopenia as now defined by multiple groups [17-21]. In addition, while there are many causes of fatigue (e.g., anemia, endocrine disorders, sleep apnea, polypharmacy, depression, and vitamin B12 deficiency), it is now well recognized that a major cause of fatigue in conditions such as heart failure is poor muscle function [22, 23]. While weight loss is not universal in sarcopenia, loss of muscle can lead to weight loss in persons who do not develop obese sarcopenia [24], and it is a hallmark of cachexia [25, 26]. Persons with multiple illnesses usually have a loss of muscle mass and function. The frailty consensus statement recommended that the treatments for frailty should be exercise (resistance and aerobic), protein-calorie supplementation, vitamin D, and reduction of polypharmacy. All of these are key treatments for sarcopenia [27]. The evidence that exercise (particularly resistance exercise) when maintained can have marked effects on frailty and sarcopenia is now very strong [28-33]. The major problem is that this form of exercise therapy needs to be provided in a long term, i.e., for at least a year, where it performs better than conventional physical therapy [34]. It is the time that health-care agencies fund “coaches” to do twice weekly home visits to do resistance exercise for a year or longer. There is increasing evidence for exercise to be coupled with high quality protein to provide optimal muscle performance [35-39]. Persons with low vitamin D have been demonstrated to have decreased strength and increased falls [40, 41]. Replacement of vitamin D in these persons appears to improve strength and decrease hip fractures [42]. Calorie replacement decreases mortality and possibly improves function in persons with malnutrition [43]. For an optimal effect, calorie supplementations should be given between meals [44]. In addition to these basic treatments, there is an increasing interest in developing drugs to treat sarcopenia [45]. Testosterone has been demonstrated to increase muscle mass and strength in older persons with and without frailty [46-51]. Its possible side effects have led to enthusiasm to produce selective androgen receptor molecules, and one of these, enobosarm, has shown some promise [52]. A variety of other drugs are in earlier stages of development for treating sarcopenia and cachexia [53]. This editorial has suggested that sarcopenia is the major cause of frailty. Frailty can be screened for by general practitioners as demonstrated by the Gerontopole Frailty Screening Tool [54, 55]. A simple screening tool, the FRAIL, takes less than 15 s to do and does not require a physician to administer it. Treatments for frailty clearly exist. For these reasons we suggest that it is time to couple sarcopenia and frailty and increase its community awareness. The German hidden garden provides a new wonderful view around each corner. If physicians begin to recognize sarcopenia and physical frailty and utilize the simple management strategies available, they will begin to have revealed to them the wonders of watching frail, and sarcopenic persons become more functional and happier in a way similar to how each few steps in a hidden garden reveals yet another wonder.
  55 in total

1.  Effect of liquid dietary supplements on energy intake in the elderly.

Authors:  Margaret-Mary G Wilson; Raj Purushothaman; John E Morley
Journal:  Am J Clin Nutr       Date:  2002-05       Impact factor: 7.045

Review 2.  Androgens and aging.

Authors:  J E Morley
Journal:  Maturitas       Date:  2001-02-28       Impact factor: 4.342

Review 3.  The roles of vitamin D in skeletal muscle: form, function, and metabolism.

Authors:  Christian M Girgis; Roderick J Clifton-Bligh; Mark W Hamrick; Michael F Holick; Jenny E Gunton
Journal:  Endocr Rev       Date:  2012-11-20       Impact factor: 19.871

4.  Frailty in older adults: evidence for a phenotype.

Authors:  L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2001-03       Impact factor: 6.053

Review 5.  Effects of vitamin D in skeletal muscle: falls, strength, athletic performance and insulin sensitivity.

Authors:  Christian M Girgis; Roderick J Clifton-Bligh; Nigel Turner; Sue Lynn Lau; Jenny E Gunton
Journal:  Clin Endocrinol (Oxf)       Date:  2014-02       Impact factor: 3.478

Review 6.  Exercise for falls and fracture prevention in long term care facilities: a systematic review and meta-analysis.

Authors:  Raimunda B Silva; Guy D Eslick; Gustavo Duque
Journal:  J Am Med Dir Assoc       Date:  2013-07-13       Impact factor: 4.669

7.  Comparison of frailty indicators based on clinical phenotype and the multiple deficit approach in predicting mortality and physical limitation.

Authors:  Jean Woo; Jason Leung; John E Morley
Journal:  J Am Geriatr Soc       Date:  2012-08-02       Impact factor: 5.562

8.  Looking for frailty in community-dwelling older persons: the Gérontopôle Frailty Screening Tool (GFST).

Authors:  B Vellas; L Balardy; S Gillette-Guyonnet; G Abellan Van Kan; A Ghisolfi-Marque; J Subra; S Bismuth; S Oustric; M Cesari
Journal:  J Nutr Health Aging       Date:  2013-07       Impact factor: 4.075

9.  Research on cachexia, sarcopenia and skeletal muscle in cardiology.

Authors:  Andrew J S Coats
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-11-16       Impact factor: 12.910

10.  Low appendicular skeletal muscle mass (ASM) with limited mobility and poor health outcomes in middle-aged African Americans.

Authors:  Theodore K Malmstrom; Douglas K Miller; Margaret M Herning; John E Morley
Journal:  J Cachexia Sarcopenia Muscle       Date:  2013-03-27       Impact factor: 12.910

View more
  35 in total

Review 1.  Muscle wasting in heart failure : The role of nutrition.

Authors:  Masakazu Saitoh; Marcelo Rodrigues Dos Santos; Stephan von Haehling
Journal:  Wien Klin Wochenschr       Date:  2016-10-19       Impact factor: 1.704

2.  Nutritional status and its effects on muscle wasting in patients with chronic heart failure: insights from Studies Investigating Co-morbidities Aggravating Heart Failure.

Authors:  Masakazu Saitoh; Marcelo Rodrigues Dos Santos; Nicole Ebner; Amir Emami; Masaaki Konishi; Junichi Ishida; Miroslava Valentova; Anja Sandek; Wolfram Doehner; Stefan D Anker; Stephan von Haehling
Journal:  Wien Klin Wochenschr       Date:  2016-11-16       Impact factor: 1.704

3.  Editorial: Weight Loss is a Major Cause of Frailty.

Authors:  B Fougère; J E Morley
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

4.  Editorial: Defining Undernutrition (Malnutrition) in Older Persons.

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

5.  Editorial: Dysphagia, Dementia and Frailty.

Authors:  M Payne; J E Morley
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

6.  Refining Low Physical Activity Measurement Improves Frailty Assessment in Advanced Lung Disease and Survivors of Critical Illness.

Authors:  Matthew R Baldwin; Jonathan P Singer; Debbie Huang; Jessica Sell; Wendy C Gonzalez; Lauren R Pollack; Mathew S Maurer; Frank F D'Ovidio; Matthew Bacchetta; Joshua R Sonett; Selim M Arcasoy; Lori Shah; Hilary Robbins; Steven R Hays; Jasleen Kukreja; John R Greenland; Rupal J Shah; Lorriana Leard; Matthew Morrell; Cynthia Gries; Patricia P Katz; Jason D Christie; Joshua M Diamond; David J Lederer
Journal:  Ann Am Thorac Soc       Date:  2017-08

7.  JCSM: growing together with cachexia and sarcopenia research.

Authors:  Ann-Kathrin Fröhlich; Monika Diek; Corinna Denecke; Stephan von Haehling; Sara Hadzibegovic; Markus S Anker
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-12       Impact factor: 12.910

Review 8.  Protein Intake and Frailty in Older Adults: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Hélio José Coelho-Junior; Riccardo Calvani; Anna Picca; Matteo Tosato; Francesco Landi; Emanuele Marzetti
Journal:  Nutrients       Date:  2022-07-05       Impact factor: 6.706

9.  Significance of frailty for predicting adverse clinical outcomes in different patient groups with specific medical conditions.

Authors:  Martin Ritt; Karl-Günter Gaßmann; Cornel Christian Sieber
Journal:  Z Gerontol Geriatr       Date:  2016-09-14       Impact factor: 1.281

10.  Moving on up: the Journal of Cachexia, Sarcopenia and Muscle.

Authors:  Stephan von Haehling; Stefan D Anker
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-09       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.